Thermo Fisher Scientific (TMO) Q4 FY24 earnings call

Thermo Fisher Scientific delivered a strong Q4 FY24, exceeding expectations with robust revenue and earnings growth, driven by operational execution and market share gains. The company is well-positioned for 2025, initiating strong adjusted EPS guidance, despite anticipated headwinds from pandemic revenue runoff and foreign exchange, with market conditions expected to improve throughout the year. The Accelerator Drug Development solution is gaining traction, leveraging combined CDMO and CRO capabilities.